

BOARD OF MEDICINE

Open Session Agenda

January 30, 2019

8:30 am to 10:00 am

BOARD MISSION STATEMENT:

“To **protect** and enhance the health, safety, and well-being of District of Columbia residents by **promoting** evidence-based best practices in health regulation, high standards of quality care and implementing policies that **prevent** adverse events.”

The Open Session Agenda continues on the next page with the ‘Board Meeting Participants’.

BOARD MEETING PARTICIPANTS:

BOARD MEMBERS:	
Andrea Anderson, MD (AA)	
Preetha Iyengar, MD (PI)	
William Strudwick, MD (WS)	
Thomas Dawson, Esq. (TD)	
Jeffrey Smith, MD (JS)	
Terrence Straub (TS)	
Archie Rich (AR)	
Vikisha Fripp, MD (VF)	
David Wessel, MD (DW)	
Thomas Smith (TS2)	
Joshua Wind, MD (JW)	
Christopher Raczynski (CR)	
Joelle Simpson (JS2)	
BOARD STAFF:	
Frank Meyers, JD – Executive Director	
Lisa Robinson – Health Licensing Specialist	
Mary Harris – Health Licensing Specialist	
Angela Braxton – Health Licensing Specialist	
Charles Annor – Health Licensing Specialist	
Emilia Moran – Investigator	
Diane Moorer – IT Support	
LEGAL STAFF:	
Suzanne Fenzel, Esq. – Board Attorney Advisor	
Ajay Gohil, Esq. – Board Attorney Advisor	

The Open Session Agenda continues on the next page with the ‘Call to Order’.¹

¹ The order in which the following agenda items are listed does not necessarily reflect the order in which the items were discussed during the meeting.

CALL TO ORDER

OS-19-01-01 ALL	<p><u>INTRODUCTIONS</u></p> <p>A. BOARD MEMBERS</p> <p>B. BOARD STAFF</p>
--------------------	--

APPROVAL OF MINUTES, CONSENT AGENDA AND STAFF REPORTS

OS-19-01-02 ALL	<p><u>BOARD/DEPARTMENT REPORT</u></p> <p>A. BOARD CHAIR’S REPORT</p> <p>B. EXECUTIVE DIRECTOR’S REPORT</p> <p>i. New Board Member Dr. Joelle Simpson has been appointed to the Board of Medicine as a physician member. Dr. Simpson works at Children’s National Medical Center and is Board Certified in Pediatrics and Emergency Medicine.</p> <p>ii. Renewal Update Late renewals will remain open until February 28th. Any license not renewed by that date will then have to submit a reinstatement application.</p> <p>iii. Licensure Census The Executive Director will provide an update on the current licensure census in the District.</p> <p>C. BOARD ATTORNEY’S REPORT</p> <p>i. Regulation Update The Board Attorney will provide an update on the status of the following regulations:</p> <p>a. Interstate Medical Licensure Compact (IMLC)</p> <p>b. Acupuncture Regulations</p>
--------------------	--

OS-19-01-03 ALL	<p><u>OPEN SESSION MINUTES</u></p> <p>Board Action: Consideration of the Open Session minutes from the December 19, 2018 meeting.</p> <p>Background: The Open Session Minutes are a record of the Board’s past meeting(s), describing the events, list of attendees, a statement of the issues considered and related responses or decisions of the Board.</p>	FM
OS-19-01-04 ALL	<p><u>OPEN CONSENT AGENDA</u></p> <p>Board Action: Consideration of the current January 30, 2019, Open Consent Agenda items for purposes of review and/or ratification of Board actions taken since the last Board meeting.</p> <p>Background: The Open Consent Agenda is a record of the decisions and/or actions taken by the Board or its staff since the last meeting of the Board.</p>	FM

The Open Session Agenda continues on the next page with ‘Misc. Items for Discussion’.

MISC. ITEMS FOR DISCUSSION

OS-19-01-05 ALL	<u>UNITED STATES MEDICAL LICENSING EXAMINATION (USMLE) REPORT</u> Board Action: To review the <i>2018 Annual Report on the USMLE to Medical Licensing Authorities in the United States</i> , provided by the FSMB and NBME. Background: The USMLE is the primary test used by nearly all medical boards in the United States for determining competency of physicians for licensure. As part of its processes, the USMLE issues an annual report, which is intended to provide state medical boards with an overview of the USMLE program and updates that may be of interest to board staff and members.	AA
OS-19-01-06 ALL	<u>PUBLIC MEMBER SCHOLARSHIP</u> Board Action: To review the information from FSMB re: Public Member Scholarships for the upcoming Annual Meeting. Background: The Federation of State Medical Boards (FSMB) recently announced it would be awarding Public Member Scholarships to encourage public member participation at the upcoming Annual Meeting. One (1) public member per state board may receive the award.	FM
OS-19-01-07 ALL	<u>LIVE. LONG. DC.</u> Board Action: To review the District’s strategic plan to reduce opioid use, misuse, and related deaths. Background: On December 24, 2018, the Department of Behavioral Health (DBH) released the District government’s plan to reduce opioid use, misuse, and related deaths, titled “Live. Long. DC.” The plan focuses on seven (7) goals with multiple strategies. These goals are: <ol style="list-style-type: none">1. Reduce legislative and regulatory barriers to create a comprehensive surveillance and response that supports sustainable solutions to emerging trends in substance use disorder, opioid-related overdose, and opioid-related fatalities.2. Educate Washington, DC residents and key stakeholders on the	FM

	<p>risks of opioid use disorders and effective prevention and treatment options.</p> <ol style="list-style-type: none"> 3. Engage health professionals and organizations in the prevention and early intervention of substance use disorder among Washington, DC residents. 4. Support the awareness and availability of, and access to, harm reduction services in Washington, DC. 5. Ensure equitable and timely access to high-quality substance use disorder treatment and recovery support services. 6. Develop and implement a shared vision between Washington, DC's justice and public health agencies to address the needs of individuals who come in contact with the criminal justice system to develop a culture of empathy for residents and their families. 7. Develop effective law enforcement strategies that reduce the supply of illegal opioids in Washington, DC. 	
<p>OS-19-01-08 ALL</p>	<p><u>OPIOID OVERDOSE TREATMENT AND PREVENTION OMNIBUS ACT OF 2018</u></p> <p>Board Action: To review the “Opioid Overdose Treatment and Prevention Omnibus Act of 2018”, recently passed by the DC Council.</p> <p>Background: The “Opioid Overdose Treatment and Prevention Omnibus Act of 2018” was recently passed by the DC City Council and sent to the Mayor for signature. The bill requires, amongst others, “prescribers” to register with the District’s Prescription Drug Monitoring Program (PDMP) by March 31, 2019.</p>	<p>FM</p>
<p>OS-19-01-09 ALL</p>	<p><u>REQUEST FOR APPROVAL OF NON-ACGME FELLOWSHIP</u></p> <p>Board Action: To review the request for approval, and supplemental documents, submitted by George Washington University Hospital regarding their non-ACGME accredited Women’s Imaging Fellowship training program.</p> <p>Background: Pursuant to 17 DCMR § 4611.2(c), applicants for an MTL II license must be participating in an ACGME, AOA or Board approved postgraduate clinical training fellowship program.</p>	<p>LR</p>

<p>OS-19-01-10 ALL</p>	<p><u>REQUEST FOR APPROVAL OF NON-ACGME FELLOWSHIP</u></p> <p>Board Action: To review the request for approval, and supplemental documents, submitted by Georgetown University Hospital regarding their non-ACGME accredited Movement Disorders Fellowship training program.</p> <p>Background: Pursuant to 17 DCMR § 4611.2(c), applicants for an MTL II license must be participating in an ACGME, AOA or Board approved postgraduate clinical training fellowship program.</p>	<p>FM</p>
<p>OS-19-01-11 ALL</p>	<p><u>PHARMACY COLLABORATIVE PRACTICE PROTOCOLS</u></p> <p>Board Action: To review the requests from Aegis Health Services and Sibley Memorial Hospital for approval of Pharmacy Collaborative Practice Protocols, as well as recommendations from the Board of Pharmacy to determine what disease states require approval from the Board of Pharmacy and the Board of Medicine before physicians and pharmacists can enter into Collaborative Practice Agreements (CPA).</p> <p>Background: Pursuant to 10 DCMR § 10002.1, a pharmacist and a physician may enter into a CPA for the management of drug therapy to manage conditions for which standard protocols exist. For conditions or diseases where there is not a protocol that is generally accepted as the clinical standard of care, the physician and pharmacist shall apply for approval, and the Board of Medicine and Pharmacy shall review the proposed treatment protocol and jointly approve or disapprove.</p> <p>The Board of Pharmacy has received two (2) requests:</p> <ol style="list-style-type: none"> 1. Aegis Health Services; and 2. Sibley Memorial Hospital. <p>In addition to the above two (2) requests, the Board of Pharmacy is proposing the following disease states do NOT need review by the Board of Pharmacy and the Board of Medicine prior to approval of the CPA:</p> <ol style="list-style-type: none"> 1. Parenteral nutrition 2. Vancomycin 3. Aminoglycosides 4. Phenytoin 	<p>FM</p>

	<ol style="list-style-type: none">5. Pain management6. Anticoagulation/Warfarin7. HIV8. Diabetes9. Hypertension10. Lipid11. Nephrology12. Depression	
--	---	--

The Open Session Agenda continues on the next page with 'Motion to Close'.

MOTION TO CLOSE

OS-19-01-12 ALL	<p><u>MOTION TO CLOSE</u></p> <p>Board Action: To go into closed session to discuss confidential matters as permitted in DC Official Code § 2-575(b).</p> <p>Background: Pursuant to DC Official Code § 2-575(b), the Board will move into the Closed Executive Session portion of the meeting to discuss the following:</p> <ol style="list-style-type: none">1. To consult with an attorney to obtain legal advice and to preserve the attorney-client privilege between an attorney and a public body, or to approve settlement agreements pursuant to § 2-575(b)(4)(a);2. Preparation, administration, or grading of scholastic, licensing, or qualifying examinations pursuant to section § 2-575(b)(6);3. To discuss disciplinary matters pursuant to section § 2-575(b)(9);4. To plan, discuss, or hear reports concerning ongoing or planned investigation of alleged criminal or civil misconduct or violations of law or regulations, if disclosure to the public would harm the investigation pursuant to section § 2-575(b)(14).	FM
--------------------	--	----

The Open Session Agenda continues on the next page with Motion to Adjourn.

MOTION TO ADJOURN		
OS-19-01-13 ALL	<p><u>MOTION TO ADJOURN</u></p> <p>Board Action: To adjourn the meeting.</p> <p>Background: At the end of every meeting, a motion to adjourn must be made in open session to close out the business of the Board.</p>	FM

This ends the Open Session Agenda.